Kelonia Therapeutics’ Journey: From Struggling Startup to $3B Biotech Powerhouse
Kelonia Therapeutics transformed from a struggling biotech startup into a $3 billion company. Discover how BioAge’s inflammation-focused strategy and...
Kelonia Therapeutics transformed from a struggling biotech startup into a $3 billion company. Discover how BioAge’s inflammation-focused strategy and...
BioAge Labs announced that its investigational cardiovascular pill, BGE-102, reduced inflammation by 85% in a Phase 1 study of obese patients. The red...